FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741775596> ?p ?o ?g. }

• W2741775596 abstract "Background: Combination therapy of nivolumab plus full-dose ipi (3 mg/kg) provided greater efficacy than either inhibitor alone but with increased toxicity (55% treatment-related adverse events [TRAEs]). Results from part 1B of the phase I/II KEYNOTE-029 study (ClinicalTrials.gov, NCT02089685) showed preliminary efficacy in pts with melanoma treated with standard-dose pembro (2 mg/kg every 3 weeks [Q3W]) + reduced-dose ipi (1 mg/kg Q3W for 4 doses). This combination appeared superior to historical studies with single-agent anti-PD-1, but 42% of pts had TRAEs. Part 1C of KEYNOTE-029 will explore 2 additional dosing regimens of this combination to further investigate efficacy and minimize the occurrence of the toxicity observed in part 1B. Methods: Eligibility criteria include age ≥18 yr; histologically confirmed unresectable stage III/IV melanoma not amenable to local therapy; no prior treatment ([neo]adjuvant treatment, excluding PD-1/PD-L1 or BRAF/MEK inhibitors is allowed, provided pts did not discontinue for TRAEs, all related AEs returned to baseline or stabilized, and relapse did not occur during or within 6 mo of treatment discontinuation for anti-CTLA-4 therapy); measurable disease per RECIST v1.1; ECOG performance status 0 or 1; no active brain metastases (baseline brain MRI required); and no active autoimmune disease requiring systemic therapy within the past 2 yr or history of pneumonitis requiring steroids. In part 1C, ~100 pts are to be randomly assigned 1:1 to receive pembro 200 mg Q3W + ipi 50 mg Q6W (arm 1) or ipi 100 mg Q12W (arm 2). Combination treatment will continue for ≤24 wk in arm 1 and ≤48 wk in arm 2, followed by pembro monotherapy for ≤24 mo or until progressive disease (PD), intolerable toxicity, patient withdrawal, or physician decision to discontinue. Tumor imaging will be performed every 6 wk until wk 24, then every 12 wk thereafter. Response will be assessed per RECIST v1.1 by independent central review (for efficacy) and modified RECIST v1.1 by investigator review (for treatment decisions). Survival follow-up will occur every 12 wk. AEs will be graded throughout the study and for 30 d thereafter per NCI CTCAE v4.0. Pts with investigator-determined, confirmed complete response (CR) who received ≥24 wk of pembro and ≥2 doses of pembro after initial CR may discontinue pembro; pts with investigator-determined, confirmed CR or very good partial response (percentage change from baseline in tumor size >60%) who received ≥1 ipi dose may discontinue ipi. Pts experiencing stable disease or better who subsequently experience PD may be eligible for a second treatment course with pembro + ipi or pembro monotherapy (maximum 17 doses of pembro and 4 doses of ipi). Eligible pts with PD may remain on treatment until a confirmatory scan ≥4 wk later. Primary end points are safety and ORR; secondary end points include PFS, OS, and duration of response. Citation Format: Michael B. Atkins, Matteo S. Carlino, Andrew G. Hill, Catriona M. McNeil, Georgina V. Long, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Wen-Jen Hwu, John A. Thompson, James Anderson, Blanca Homet Moreno, Nageatte Ibrahim, Antoni Ribas. KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT065. doi:10.1158/1538-7445.AM2017-CT065" @default.
• W2741775596 created "2017-08-08" @default.
• W2741775596 creator A5000993397 @default.
• W2741775596 creator A5024566503 @default.
• W2741775596 creator A5028479135 @default.
• W2741775596 creator A5028949419 @default.
• W2741775596 creator A5031661938 @default.
• W2741775596 creator A5037357027 @default.
• W2741775596 creator A5052526230 @default.
• W2741775596 creator A5054723003 @default.
• W2741775596 creator A5055983682 @default.
• W2741775596 creator A5061348179 @default.
• W2741775596 creator A5070576000 @default.
• W2741775596 creator A5082742595 @default.
• W2741775596 creator A5083061830 @default.
• W2741775596 creator A5083745558 @default.
• W2741775596 date "2017-07-01" @default.
• W2741775596 modified "2023-10-11" @default.
• W2741775596 title "Abstract CT065: KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma" @default.
• W2741775596 doi "https://doi.org/10.1158/1538-7445.am2017-ct065" @default.
• W2741775596 hasPublicationYear "2017" @default.
• W2741775596 type Work @default.
• W2741775596 sameAs 2741775596 @default.
• W2741775596 citedByCount "0" @default.
• W2741775596 crossrefType "proceedings-article" @default.
• W2741775596 hasAuthorship W2741775596A5000993397 @default.
• W2741775596 hasAuthorship W2741775596A5024566503 @default.
• W2741775596 hasAuthorship W2741775596A5028479135 @default.
• W2741775596 hasAuthorship W2741775596A5028949419 @default.
• W2741775596 hasAuthorship W2741775596A5031661938 @default.
• W2741775596 hasAuthorship W2741775596A5037357027 @default.
• W2741775596 hasAuthorship W2741775596A5052526230 @default.
• W2741775596 hasAuthorship W2741775596A5054723003 @default.
• W2741775596 hasAuthorship W2741775596A5055983682 @default.
• W2741775596 hasAuthorship W2741775596A5061348179 @default.
• W2741775596 hasAuthorship W2741775596A5070576000 @default.
• W2741775596 hasAuthorship W2741775596A5082742595 @default.
• W2741775596 hasAuthorship W2741775596A5083061830 @default.
• W2741775596 hasAuthorship W2741775596A5083745558 @default.
• W2741775596 hasConcept C121608353 @default.
• W2741775596 hasConcept C126322002 @default.
• W2741775596 hasConcept C143998085 @default.
• W2741775596 hasConcept C197934379 @default.
• W2741775596 hasConcept C2777288759 @default.
• W2741775596 hasConcept C2777658100 @default.
• W2741775596 hasConcept C2777701055 @default.
• W2741775596 hasConcept C2777714996 @default.
• W2741775596 hasConcept C2778715236 @default.
• W2741775596 hasConcept C2779524853 @default.
• W2741775596 hasConcept C2780030458 @default.
• W2741775596 hasConcept C2780057760 @default.
• W2741775596 hasConcept C2781433595 @default.
• W2741775596 hasConcept C31760486 @default.
• W2741775596 hasConcept C502942594 @default.
• W2741775596 hasConcept C535046627 @default.
• W2741775596 hasConcept C71924100 @default.
• W2741775596 hasConceptScore W2741775596C121608353 @default.
• W2741775596 hasConceptScore W2741775596C126322002 @default.
• W2741775596 hasConceptScore W2741775596C143998085 @default.
• W2741775596 hasConceptScore W2741775596C197934379 @default.
• W2741775596 hasConceptScore W2741775596C2777288759 @default.
• W2741775596 hasConceptScore W2741775596C2777658100 @default.
• W2741775596 hasConceptScore W2741775596C2777701055 @default.
• W2741775596 hasConceptScore W2741775596C2777714996 @default.
• W2741775596 hasConceptScore W2741775596C2778715236 @default.
• W2741775596 hasConceptScore W2741775596C2779524853 @default.
• W2741775596 hasConceptScore W2741775596C2780030458 @default.
• W2741775596 hasConceptScore W2741775596C2780057760 @default.
• W2741775596 hasConceptScore W2741775596C2781433595 @default.
• W2741775596 hasConceptScore W2741775596C31760486 @default.
• W2741775596 hasConceptScore W2741775596C502942594 @default.
• W2741775596 hasConceptScore W2741775596C535046627 @default.
• W2741775596 hasConceptScore W2741775596C71924100 @default.
• W2741775596 hasLocation W27417755961 @default.
• W2741775596 hasOpenAccess W2741775596 @default.
• W2741775596 hasPrimaryLocation W27417755961 @default.
• W2741775596 hasRelatedWork W1517787104 @default.
• W2741775596 hasRelatedWork W1978028546 @default.
• W2741775596 hasRelatedWork W1986004507 @default.
• W2741775596 hasRelatedWork W1990675339 @default.
• W2741775596 hasRelatedWork W2000651446 @default.
• W2741775596 hasRelatedWork W2079571738 @default.
• W2741775596 hasRelatedWork W2211219919 @default.
• W2741775596 hasRelatedWork W2252676806 @default.
• W2741775596 hasRelatedWork W2260073192 @default.
• W2741775596 hasRelatedWork W2322553328 @default.
• W2741775596 hasRelatedWork W2404057211 @default.
• W2741775596 hasRelatedWork W2477245600 @default.
• W2741775596 hasRelatedWork W2793901188 @default.
• W2741775596 hasRelatedWork W2886537875 @default.
• W2741775596 hasRelatedWork W3006202513 @default.
• W2741775596 hasRelatedWork W3039168692 @default.
• W2741775596 hasRelatedWork W3083442449 @default.
• W2741775596 hasRelatedWork W3083632537 @default.
• W2741775596 hasRelatedWork W3129208430 @default.
• W2741775596 hasRelatedWork W3209220541 @default.
• W2741775596 isParatext "false" @default.
• W2741775596 isRetracted "false" @default.
• W2741775596 magId "2741775596" @default.
• W2741775596 workType "article" @default.